Section
Patients with primary cancer who had pre-diagnostic CHIP faced a higher risk of second cancers, especially blood cancers. The findings suggest CHIP may help identify survivors who need closer long-term monitoring.
In patients with head and neck cancer, living in the most socioeconomically disadvantaged areas was associated with poorer pretreatment head and neck cancer–specific quality of life, while associations with other quality-of-life domains wer
An early single-institution series suggests histotripsy may offer noninvasive local control for neuroendocrine liver metastases, with complete response after full-coverage treatment but important safety concerns, particularly acute kidney i
In Swedish and Chinese cohorts, cold knife conization was associated with lower recurrent cervical lesion risk and faster HPV clearance than LEEP, although important questions remain about residual confounding, obstetric trade-offs, and pro
A fine-tuned ensemble of tabular foundation models moderately predicted pathological complete response after TNT and showed potential to support watch-and-wait selection after recalibration.
In a 298-patient endometrial cancer cohort, HRR gene alterations were rare, enriched in aggressive tumor subsets, but did not predict survival or platinum sensitivity beyond integrated molecular classification.
A single-center validation study shows the RETREAT score reliably predicts long-term HCC recurrence after liver transplantation and identifies patients with markedly different recurrence-free and overall survival trajectories.
Extended follow-up from ASTRUM-005 shows serplulimab plus chemotherapy improves long-term survival in untreated extensive-stage small cell lung cancer, with manageable safety and encouraging patient-reported outcomes.
A phase 1 study suggests non-gene-edited allogeneic CD19 CAR-T therapy can induce remissions in relapsed or refractory B-ALL without observed GVHD, though durability remains limited and larger trials are needed.
In stage I ovarian sex cord-stromal tumors, stage IC and tumor morcellation were independently associated with recurrence, while minimally invasive surgery itself was not after adjustment.
In a large Hong Kong cohort with newly diagnosed type 2 diabetes, higher early HbA1c exposure was associated with greater long-term cancer risk, suggesting that glycaemic control soon after diagnosis may matter more than later improvement.
A large Texas registry study found that treatment delays beyond 6 weeks were independently associated with worse survival in early-onset colorectal cancer, with language barriers identified as a potentially modifiable contributor.
Preclinical data suggest fingolimod and mocravimod can resensitize NRAS-mutated FLT3-ITD AML to FLT3 inhibitors by suppressing ERK-SPHK1-AKT signaling, including activity in patient blasts and an orthotopic mouse model.
A multicenter study found that immune checkpoint inhibitor–associated uveitis risk varies by cancer type and drug class, with melanoma showing the highest intrinsic risk and RCC risk largely linked to ipilimumab/nivolumab exposure.
TCGA-based transcriptome analysis suggests high CCNA2 and E2F1 expression marks poor progression-free survival and probable platinum insensitivity in endometrial cancer, supporting pretreatment molecular stratification and alternative thera
Y90 radioembolization downstaged about one-quarter of HCC patients with portal vein tumor thrombosis to transplant eligibility, and those who received liver transplantation had markedly better cancer-related outcomes and survival.
This review explores how tumour-infiltrating adipocytes release 12,13-DiHOME to trigger neutrophil ferroptosis and CXCL2 production, ultimately subverting CD8+ T cell-mediated immunity in pancreatic ductal adenocarcinoma.
Bacterial quorum-sensing molecules, especially C6-scAHL, were elevated in long-standing ulcerative colitis and promoted colon tumor growth in mice, suggesting a new microbiome-driven pathway for colitis-associated cancer.
In papillary thyroid carcinoma treated with thyroidectomy and RAI, TgAb levels above the assay’s limit of quantification identified patients with higher long-term recurrence risk despite undetectable serum thyroglobulin.
Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in hormone receptor-positive, ERBB2-negative advanced breast cancer with manageable toxicity and preserved quality of life.
